Work

78. Regulation of Immune Responses Against Factor VIII Following Nonviral Gene Transfer in Hemophilia A and FOXP3 Transgenic Mouse Models

Year: 2006

Type: article

Abstract: The success of naked DNA gene transfer as a novel approach to the treatment of hemophilia A has been limited by the formation of inhibitory antibodies against factor VIII (FVIII). Approximately 25–30% of hemophilia A patients produce inhibitory antibodies in response to FVIII protein replacement therapy. Potential gene therapy techniques used to treat hemophilia A have also resulted in a significant humoral immune response in murine models (Ye et al., 2004). The critical role of CD4+CD25+ regulatory T (Treg) cells in controlling autoimmune and alloimmune responses has recently been recognized.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2006.08.095